New drug cocktail aims to shrink Hard-to-Treat liver and bile duct tumors
NCT ID NCT03482102
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with radiation can shrink tumors in people with advanced liver or bile duct cancer. The study enrolled 37 adults whose cancer had spread or could not be removed by surgery. The goal is to see how many patients have their tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab, tremelimumab, and radiation therapy
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced liver or bile duct cancer, potentially shrinking tumors and extending life.
What could go wrong
This is a small, early-phase trial with only 37 participants, so results may not apply to everyone. The drugs can cause serious immune-related side effects, and the cancer may still progress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States